Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 5Kidney Neoplasms 5von Hippel-Lindau Disease 4Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

aldesleukin 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Brachytherapy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1talazoparib 1liposomal doxorubicin 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1belzutifan 1Therapeutic Touch 1Surveys and Questionnaires 1Specimen Handling 1Sonazoid 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Observation 1Nivolumab 1Methods 1Interviews as Topic 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × belzutifan × 1 year × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡